J INTERN MED:氢氯噻嗪的使用与唇癌的发生风险增加密切相关!

2017-05-30 xing.T MedSci原创

由此可见,氢氯噻嗪的使用与唇癌的发生风险增加密切相关。

在美国和西欧,利尿剂氢氯噻嗪是最常见的处方药,但有证据表明氢氯噻嗪的使用会增加唇癌的发生风险。近日,内科学领域权威杂志Journal of Internal Medicine上发表一篇研究文章,研究人员旨在评估氢氯噻嗪使用与嘴唇鳞状细胞癌之间的相关性。

研究人员使用丹麦全国注册数据进行了一项病例对照研究。从癌症登记处(2004-2012年),研究人员确定了633例嘴唇鳞状细胞癌(SCC)的患者,并采用风险集采样策略将其匹配了63067名对照者。研究人员从处方登记中心确定了氢氯噻嗪的使用(1995-2012年),并根据累积使用来确定。调整预先定义的从人口、处方和病人登记中心获得的潜在混杂因素后,研究人员应用条件Logistic回归分析计算了与氢氯噻嗪使用相关的嘴唇SCC比值比(OR)。

研究人员发现曾经使用氢氯噻嗪导致嘴唇SCC调整的比值比为2.1(95%可信区间(CI)为1.7-2.6),对于高剂量(≥25000毫克)氢氯噻嗪,其比值比增加至3.9(95%CI为3.0-4.9)。研究人员发现存在明确的剂量反应效应(P<0.001),最高累积剂量的氢氯噻嗪(≥100000毫克)呈现的比值比为7.7(95%CI为5.7-10.5)。研究人员没有发现嘴唇癌与其他利尿药或非利尿降压药的使用存在相关性。假设存在因果关系,研究人员估计11%的嘴唇鳞状细胞癌病例可以归因于氢氯噻嗪的使用。

由此可见,氢氯噻嗪的使用与唇癌的发生风险增加密切相关。

原始出处:

Anton Pottegård,et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J INTERN MED. 2017. http://onlinelibrary.wiley.com/doi/10.1111/joim.12629/full

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643226, encodeId=6b9816432268f, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Wed Dec 20 07:16:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205237, encodeId=d69e20523e1e, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 01 12:55:12 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360544, encodeId=4896136054420, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607598, encodeId=2125160e59886, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-12-20 fangcong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643226, encodeId=6b9816432268f, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Wed Dec 20 07:16:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205237, encodeId=d69e20523e1e, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 01 12:55:12 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360544, encodeId=4896136054420, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607598, encodeId=2125160e59886, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-06-01 luominglian113

    涨知识了,谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1643226, encodeId=6b9816432268f, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Wed Dec 20 07:16:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205237, encodeId=d69e20523e1e, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 01 12:55:12 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360544, encodeId=4896136054420, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607598, encodeId=2125160e59886, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643226, encodeId=6b9816432268f, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Wed Dec 20 07:16:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205237, encodeId=d69e20523e1e, content=涨知识了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 01 12:55:12 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360544, encodeId=4896136054420, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607598, encodeId=2125160e59886, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=)]

相关资讯

AIM:降压药可能增加唇癌风险

《内科学文献》杂志8月6日在线发表的一项研究显示,常用的光敏性降压药物可使唇癌的发病风险增加1~3倍。氢氯噻嗪、氨苯蝶啶和硝苯地平均在此列,赖诺普利也有嫌疑(Arch. Intern. Med. 2012 Aug. 6 [doi:10.1001/archinternmed.2012.2754])。 在这项纳入23,616例非西班牙裔白人高血压患者的研究中,氢氯噻嗪利尿剂、氢氯噻嗪-氨苯蝶啶和钙通

JACC:低剂量的氯噻酮和氢氯噻嗪,谁抗高血压效果更好?

噻嗪类和噻嗪样利尿剂正在越来越多地以更低的剂量被使用。12.5毫克剂量的氢氯噻嗪(HCTZ)在美国仍然是最常用的处方抗高血压药物。该研究比较了氯噻酮,每天6.25毫克,与氢氯噻嗪,每天12.5毫克相比,24小时动态血压(ABP)监测和评价疗效。因为HCTZ已被认为是一种短效药,第三种比较是与加入缓释制剂后进行了比较(HCTZ可控缓释[CR])。该12周的比较,双盲,门诊研究随机分配54例1级高血压

J Hypertens:替米沙坦比氢氯噻嗪降舒张压更优

对于饮食喜咸,多药联合依从性又不好的轻中度高血压患者,采用单药治疗效果如何?近期,北京大学医学部乔治健康研究所和北京大学人民医院学者发表于J Hypertens上的一项研究表明,对于这部分患者,每天40 mg的替米沙坦或25 mg的氢氯噻嗪都有效,而前者降压效果明显更好,尤其是舒张压。研究显示,在接受替米沙坦或氢氯噻嗪的两组轻中度高血压患者,治疗后15天、30天和60天时,替米沙坦组平均收缩压/舒

Dermatol Surg:长期用氢氯噻嗪或增皮肤癌风险

氢氯噻嗪是一种降压的老药,近期来自美国佛罗里达州州立大学Mohs显微手术中心皮肤肿瘤科几位医师的研究表明,氢氯噻嗪或会增加皮肤癌风险。研究者认为,氢氯噻嗪是一种已知的光敏剂,对于皮肤癌高发的人群,比如非西班牙裔白种人,减少应用或是一种有助于降低发病的因素。他们建议,这类患者尽可能更换降压药。在这项研究中,研究者共对其医疗中心5年收治的75例皮肤癌患者用药清单进行了分析。其中,终身鳞状细胞癌超过20

Lancet:不同体重人群的利尿剂降压治疗存在差异

     美国学者的一项研究表明,体重正常和肥胖患者的高血压可能经由不同机制介导。基于噻嗪类的治疗对体重正常患者的心血管保护作用可能逊色于肥胖患者,但基于氨氯地平的治疗则可在不同体质指数(BMI)患者中发挥相同效应。论文于2012年12月5日在线发表于《柳叶刀》(Lancet)。   此项研究基于BMI将ACCOMPLISH试验受试人群分为肥胖(BMI ≥30,n=570

J Hypertens:高钠摄入的高血压人群降压治疗选择替米沙坦还是氢氯噻嗪?

由此可见,替米沙坦和氢氯噻嗪都是高钠摄入量的高血压患者有效地治疗药物。相比于氢氯噻嗪,替米沙坦具有更好的舒张压降低效果和较少的低血钾。需要进一步的研究以评估PP较大的患者氢氯噻嗪合理的优势效果。